Evidence map›Paper›PMID 41143946›Full record

ArticleInternational journal of hematology2026

Epcoritamab as bridging therapy to successful second allogeneic HSCT in relapsed DLBCL after UCBT and CAR T cell therapy.

Yui Chikagawa, Daiki Higashi, Satoomi Sakai, Hiroki Yoshino, Yuki Nukii, Hiroki Mura, Shunichiro Nakagawa, Shinya Yamada, Takeshi Yoroidaka, Tatsuya Imi and 8 more

Abstract readCase Reports
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Yui ChikagawaDepartment of Internal Medicine, Komatsu Municipal Hospital, 60, Mukaimotoori-Machi, Komatsu, Ishikawa, 923-8560, Japan. ychikagawa.n1@gmail.com.ORCID http://orcid.org/0000-0002-7623-1900
Daiki HigashiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Satoomi SakaiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Hiroki YoshinoDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Yuki NukiiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Hiroki MuraDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Shunichiro NakagawaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Shinya YamadaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Takeshi YoroidakaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Tatsuya ImiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Yoshitaka ZaimokuDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Hiroyuki MaruyamaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Kohei HosokawaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Go AokiDepartment of Internal Medicine, Komatsu Municipal Hospital, 60, Mukaimotoori-Machi, Komatsu, Ishikawa, 923-8560, Japan.
Akiyo YoshidaDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Hiroyuki TakamatsuDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Hirohito YamazakiDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.
Toshihiro MiyamotoDepartment of Hematology, Faculty of Medicine, Institute of Medical, Pharmaceutical, and Health Sciences, Kanazawa University, 13-1, Takara-Machi, Kanazawa, Ishikawa, 920-8641, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 53-year-old woman experienced relapse of diffuse large B cell lymphoma (DLBCL) 16 years after achieving a first complete metabolic response (CMR). Despite initially being refractory to salvage chemotherapy, she achieved a second CMR and underwent umbilical cord blood transplantation (UCBT). On day 119 post-transplantation, she experienced a second relapse and received chimeric antigen receptor T (CAR T) cell therapy, achieving a third remission without cytokine release syndrome or graft-versus-host disease (GVHD). However, a third relapse occurred seven months after CAR T cell therapy. Epcoritamab treatment was initiated, resulting in CMR without severe complications. Subsequently, the patient underwent curative unrelated allogeneic peripheral blood hematopoietic stem cell transplantation (HSCT). She experienced no severe transplant-related complications, including serious GVHD or infections. She has remained in CMR for > 1 year after the second transplant. Epcoritamab appears to be an effective and safe treatment option for DLBCL relapse, even after both UCBT and CAR T cell therapy, suggesting that bridging therapy with epcoritamab followed by a second allogeneic HSCT may achieve long-term survival.

Indexed as

Cord Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationImmunotherapy, AdoptiveLymphoma, Large B-Cell, DiffuseFemaleHumansMiddle AgedReceptors, Chimeric AntigenRecurrenceTransplantation, HomologousTreatment OutcomeReceptors, Chimeric AntigenAllogeneic hematopoietic stem cell transplantationBridging therapyChimeric antigen receptor T cell therapy failureEpcoritamabRelapsed or refractory diffuse large B cell lymphoma

Identifiers

PMID41143946

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.